The oral antiviral clinical candidate PF-07321332, a SARS-CoV2-3CL protease inhibitor, has demonstrated potent in vitro anti-viral activity against SARS-CoV-2, as well as activity against other coronaviruses, suggesting potential for use in the treatment of COVID-19 as well as potential use to address future coronavirus threats.Protease inhibitors bind to a viral enzyme (called a protease), preventing the virus from replicating in the cell. Protease inhibitors have been effective at treating other viral pathogens such as HIV and hepatitis C virus, both alone and in combination with other antivirals. Currently marketed therapeutics that target viral proteases are not generally associated with toxicity and as such, this class of molecules may potentially provide well-tolerated treatments against COVID-19.
Covid has HIV class spike proteins little surprise an HIV drug would have effects against it. Makes one wonder if the PREP protocol for HIV would be a prophylaxis to it like it is for HIV. biological males can take PREP nearly indefinitely to.prevent HIV seroconversion upon exposure. PREP also targets the spike proteins and inhibits HIV from invading and replication in the ACE2 cells.